Eli Lilly candidate shows weight loss at 11 percent in phase III trial

Initial test results form Eli Lilly's phase III study show that the drug candidate tirzepatide can generate an 11 percent weight loss with the highest tested dosis at 15 mg.
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030

US pharmaceutical firm Eli Lilly have oresented the initial results for the phase III study for the company's drug candidate tirzepatide against obesity.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading